The U.S. Food and Drug Administration granted orphan drug designation to ProMetic Life Sciences Inc.'s inter-alpha-inhibitor-proteins for treating necrotizing enterocolitis.

Necrotizing enterocolitis is the most common acquired gastrointestinal disease affecting premature infants. It is characterized by damage to the intestinal wall, leading to perforation of the intestine and spilled stool into the infant's abdomen.